DrugPatentWatch Database Preview
Drugs in Development Information for QAW039
Email this page to a colleague
» See Plans and PricingWhat is the development status for investigational drug QAW039?
QAW039 is an investigational drug.
There have been 18 clinical trials for QAW039.
The most recent clinical trial was a Phase 2 trial, which was initiated on December 7th 2018.
The most common disease conditions in clinical trials are Asthma, Eosinophilia, and Bronchial Diseases. The leading clinical trial sponsors are Novartis Pharmaceuticals and [disabled in preview].
There are six US patents protecting this investigational drug and sixty-two international patents.
Summary for QAW039
| US Patents | 6 |
| International Patents | 62 |
| US Patent Applications | 12 |
| WIPO Patent Applications | 14 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2018-12-07) |
| Vendors | 28 |
Recent Clinical Trials for QAW039
| Title | Sponsor | Phase |
|---|---|---|
| Mechanistic Study of Anti-inflammatory Effects of Fevipiprant in Patients With Eosinophilic Asthma. | Novartis Pharmaceuticals | Phase 2 |
| A Proof-of-mechanism Study of Multiple, Oral Doses of Fevipiprant (QAW039) in COPD Patients With Eosinophilia | Novartis Pharmaceuticals | Phase 2 |
| Pharmacokinetics, Safety and Tolerability of Fevipiprant Delivered Via a Once Daily Chewable Tablet in Children Aged 6 to < 12 Years With Asthma | Novartis Pharmaceuticals | Phase 2 |
Clinical Trial Summary for QAW039
Top disease conditions for QAW039
Top clinical trial sponsors for QAW039
US Patents for QAW039
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| QAW039 | Start Trial | Pyrrolopyridine derivatives and their use as Crth2 antagonists | Novartis AG (Basel, CH) | Start Trial |
| QAW039 | Start Trial | Pyrrolopyridine derivatives and their use as CRTH2 antagonists | Novartis AG (Basel, CH) | Start Trial |
| QAW039 | Start Trial | Organic compounds | Novartis AG (Basel, CH) | Start Trial |
| QAW039 | Start Trial | Pyrrolopyridine derivatives and their use as CRTH2 antagonists | Novartis AG (Basel, CH) | Start Trial |
| QAW039 | Start Trial | Pyrrolopyridine derivatives and their use as CRTH2 antagonists | Novartis AG (Basel, CH) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for QAW039
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| QAW039 | Argentina | 049443 | 2024-06-17 | Start Trial |
| QAW039 | Austria | 378338 | 2024-06-17 | Start Trial |
| QAW039 | Australia | 2005254681 | 2024-06-17 | Start Trial |
| QAW039 | Brazil | PI0512060 | 2024-06-17 | Start Trial |
| QAW039 | Canada | 2569125 | 2024-06-17 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
